5-(4-chloro-3-nitrophenyl)-2-pyrimidinamine | 742700-78-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 5-(4-chloro-3-nitrophenyl)-2-pyrimidinamine
• 英文别名: 5-(4-Chloro-3-nitrophenyl)pyrimidin-2-amine
• CAS: 742700-78-3
• 化学式: C₁₀H₇ClN₄O₂
• 分子量: 250.644
• InChiKey: GRJSGQLDUOYOSI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  97.6
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  5-(4-chloro-3-nitrophenyl)-2-pyrimidinamine 在 sodium hydroxide 作用下， 以 乙二醇乙醚 为溶剂， 反应 10.0h， 生成 5-(3-Oxy-2-o-tolyl-1H-benzoimidazol-5-yl)-pyrimidin-2-ylamine
  参考文献：
  名称：

  Structural Studies on Bioactive Compounds. 39. Biological Consequences of the Structural Modification of DHFR-Inhibitory 2,4-Diamino-6-(4-substituted benzylamino-3-nitrophenyl)-6-ethylpyrimidines (‘benzoprims')

  摘要：

  Benzimidazole-N-oxide modifications of potent lipophilic dihydrofolate reductase (DHFR) inhibitors (e.g., methylbenzoprim 1 and dichlorobenzoprim 2) have been prepared by basepromoted cyclization of the nitrophenylbenzylamino groups to explore the possibility that abrogation of DHFR-inhibitory activity might reveal clues to an alternative anti-ras mechanism. Examples of the new series had only low growth inhibitory activities (Gi(50) generally > 50 muM) against colon HCT116 and lung HT29 cell lines but, unlike methylbenzoprim, this activity was unaffected by hypoxanthine/thymidine rescue.

  DOI：

  10.1021/jm040785+
• 作为产物：
  描述：

  5-(4-氯苯基)-2-嘧啶胺 在 硫酸 、 硝酸 作用下， 反应 2.0h， 生成 5-(4-chloro-3-nitrophenyl)-2-pyrimidinamine
  参考文献：
  名称：

  Structural Studies on Bioactive Compounds. 39. Biological Consequences of the Structural Modification of DHFR-Inhibitory 2,4-Diamino-6-(4-substituted benzylamino-3-nitrophenyl)-6-ethylpyrimidines (‘benzoprims')

  摘要：

  Benzimidazole-N-oxide modifications of potent lipophilic dihydrofolate reductase (DHFR) inhibitors (e.g., methylbenzoprim 1 and dichlorobenzoprim 2) have been prepared by basepromoted cyclization of the nitrophenylbenzylamino groups to explore the possibility that abrogation of DHFR-inhibitory activity might reveal clues to an alternative anti-ras mechanism. Examples of the new series had only low growth inhibitory activities (Gi(50) generally > 50 muM) against colon HCT116 and lung HT29 cell lines but, unlike methylbenzoprim, this activity was unaffected by hypoxanthine/thymidine rescue.

  DOI：

  10.1021/jm040785+

文献信息

• NOVEL CHEMICAL COMPOUNDS
  申请人：Duffy Kevin

  公开号：US20090203692A1

  公开（公告）日：2009-08-13

  This invention relates to newly identified compounds for inhibiting hYAK3 proteins and methods for treating diseases associated with hYAK3 activity.

  本发明涉及新鉴定的化合物，用于抑制hYAK3蛋白质，并用于治疗与hYAK3活性相关的疾病的方法。
• WO2006/127458
  申请人：——

  公开号：——

  公开（公告）日：——
• [EN] NOVEL CHEMICAL COMPOUNDS<br/>[FR] NOUVEAUX COMPOSES CHIMIQUES
  申请人：SMITHKLINE BEECHAM CORP

  公开号：WO2006127458A2

  公开（公告）日：2006-11-30

  [EN] This invention relates to newly identified compounds for inhibiting hYAK3 proteins and methods for treating diseases associated with hYAK3 activity.
  [FR] La présente invention concerne des composés récemment identifiés qui permettent d'inhiber les protéines hYAK3, ainsi que des méthodes de traitement de maladies associées à l'activité hYAK3.
• Structural Studies on Bioactive Compounds. 39. Biological Consequences of the Structural Modification of DHFR-Inhibitory 2,4-Diamino-6-(4-substituted benzylamino-3-nitrophenyl)-6-ethylpyrimidines (‘benzoprims')
  作者：Marianne L. Richardson、Karen A. Croughton、Charles S. Matthews、Malcolm F. G. Stevens

  DOI：10.1021/jm040785+

  日期：2004.7.1

  Benzimidazole-N-oxide modifications of potent lipophilic dihydrofolate reductase (DHFR) inhibitors (e.g., methylbenzoprim 1 and dichlorobenzoprim 2) have been prepared by basepromoted cyclization of the nitrophenylbenzylamino groups to explore the possibility that abrogation of DHFR-inhibitory activity might reveal clues to an alternative anti-ras mechanism. Examples of the new series had only low growth inhibitory activities (Gi(50) generally > 50 muM) against colon HCT116 and lung HT29 cell lines but, unlike methylbenzoprim, this activity was unaffected by hypoxanthine/thymidine rescue.